Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
July 29 — A class of Caris Life Sciences Inc. stock option holders were awarded more than $16.2 million in damages, after a Delaware judge concluded that the medical diagnostics company purposely undervalued two of its spun-off business units to avoid tax consequences.
In a July 28 opinion, Vice Chancellor J. Travis Laster found that when Caris used a complex spin/merger structure to effectuate the sale of its pathology unit, it improperly valued two spun-off business units to minimize the taxes of controlling stockholders.
According to the court, by inaccurately valuing the spinoffs, Caris violated a stock incentive plan requiring the company to repurchase cancelled employee stock options for the amount that the stocks' “Fair Market Value” exceeded the exercise price.
After the transaction, the plaintiff, a former Caris employee option holder, argued that the share value attributed to the spinoffs was not a good-faith determination and resulted from an arbitrary and capricious process.
Laster observed that Caris Chief Executive Officer David Halbert, a 70.4 percent owner, and Chief Financial Officer Gerard Martino faced the choice of a realistic valuation of the spun-off business units, resulting in the CEO facing tax liability, or a zero-tax valuation that would generate an unrealistically low payout for options.
The court found that the company failed to make a good-faith determination because evidence introduced at trial proved that Halbert and Martino both subjectively believed the value of the spun-off business units to be much higher. Specifically, the court observed that there was evidence that the valuation process was manipulated to reduce tax liability, and that Martino and Halbert's credibility was undermined by testimony that they had “no problem giving false projections” to potential buyers of the units.
In the alternative, the court also concluded that the process Caris followed to determine the fair market value was arbitrary and capricious because it relied on a valuation prepared for a different purpose—ensuring that the spinoff would result in zero corporate-level tax.
Laster specifically took aim at a valuation prepared by Grant Thornton that admittedly copied another accounting firm's analysis prepared for the purpose of the intercompany tax transfer.
“The Grant Thornton report deserves separate mention because its contents were so flawed as to support both an inference of bad faith and a finding the process was arbitrary and capricious,” the judge wrote. “Previous Delaware decisions have criticized erroneous or seemingly motivated analyses by financial advisors, but the Grant Thornton report reached a new low.”
Moreover, the court found that the company breached the stock incentive plan in two additional ways. First, the company failed to comply with a portion of the plan obligating its board to determine the fair market value of the company's stock.
By instead treating the controlling stockholder's sign-off on the determination of how much option holders would receive as sufficient, the board did not act in accordance with Delaware's bedrock principle of “director primacy,” Laster concluded.
The company also breached its agreement with option holders by withholding a portion of their merger consideration in escrow, even though the company was required to do so under the merger agreement.
“The relationship between Caris and its option holders was governed by contract,” Laster wrote. “The operative contract was not the Merger Agreement, but rather the Plan.”
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Yin Wilczek at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/KURT_FOX_on_behalf_of_himself_and_all_others_similarly_situated_P.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)